BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/12/2026 10:07:35 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-08-15 04:41 |
|
Peer-Review Started |
|
2025-08-15 04:42 |
|
First Decision by Editorial Office Director |
|
2025-09-12 05:34 |
|
Return for Revision |
|
2025-09-12 05:34 |
|
Revised |
|
2025-09-21 13:15 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-20 02:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-20 10:52 |
|
Articles in Press |
|
2025-11-20 10:52 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-04 02:09 |
|
Publish the Manuscript Online |
|
2026-01-12 10:07 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Patients with hepatocellular carcinoma achieving a complete response to sorafenib: Three case reports and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hana Lučev, Gordan Adžić, Stjepko Pleština and Juraj Prejac |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Gordan Adžić, MD, Department of Oncology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb 10000, Croatia. gordan.adzic@gmail.com |
| Key Words |
Hepatocellular carcinoma; Sorafenib; Complete response; Tyrosine kinase inhibitor; Case report |
| Core Tip |
Complete responses to sorafenib in advanced hepatocellular carcinoma are extremely rare. This case series reports 3 patients who, despite having advanced hepatocellular carcinoma with features like portal vein thrombosis and extrahepatic spread, achieved durable complete responses on sorafenib therapy. Predictive biomarkers for sorafenib response remain unknown, although dermatologic toxicity and non-viral etiology may be associated with favorable outcomes. These findings support the continued utility of tyrosine kinase inhibitors in selected patients, particularly when immunotherapy is contraindicated or unavailable. |
| Publish Date |
2026-01-12 10:07 |
| Citation |
Lučev H, Adžić G, Pleština S, Prejac J. Patients with hepatocellular carcinoma achieving a complete response to sorafenib: Three case reports and review of literature. World J Gastrointest Oncol 2026; 18(1): 113099 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i1/113099.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i1.113099 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
